Abbott and Boston Scientific are among the investors in SetPoint, whose neurostimulation device gained FDA approval last ...

Shortly after obtaining a green light from the FDA, SetPoint Medical announced $140 million in new funding to juice the commercialization of its neuromodulation implant for rheumatoid art | Shortly ...

The shares of biotech companies fell after news that ousted regulator Vinay Prasad is set to go back to the US Food and Drug Administration. Prasad had previously overruled his own scientific review ...

Vinay Prasad, the U.S. Food and Drug Administration's top vaccine regulator, is returning to his post less than two weeks ...

Our fair value estimate for Olympus is JPY 2,390 per share. It implies a terminal enterprise value/EBITDA multiple of 12.8 times, roughly in line with its Japanese peers but lower than leading US ...

SetPoint Medical announced that it raised $140 million in private financing, including a second Series C tranche and its ...

It should be obvious that women have different health needs than men. Women have reproductive and gynecological health issues ...

Stifel’s Barry Bannister says stocks are due for a big drop and thinks investors should play defense with staples and ...

There are a number of emerging therapies in development for lowering lipoprotein(a), and later-stage trials are underway.Interest continues to grow in lipoprotein(a), commonly known as Lp(a), both as ...

Combining approximately $120 million from the former Helix II trust account (reflecting a final redemption rate of approximately 39% which is the second lowest redemption rate for a biotech de-SPAC ...

Bruker Corporation BRKR delivered adjusted earnings per share (EPS) of 32 cents for the second quarter of 2025, down 38.5% ...

In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe th ...